Esophageal squamous cell carcinoma · 5 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and Etoposide (EP) Variant #01 | — | R 4 264 | 42d | — | 16.0 mo | — | — | 1 |
Cisplatin and Fluorouracil (CF) Variant #29 | — | R 1 900 | 21d | — | 26.1 mo | — | — | 2 |
Cisplatin and Paclitaxel (TP) Variant #01 | — | R 716 | 10d | — | 27.5 mo | — | — | 3 |
DCF N/A - secondary systemic drug | — | R 228 | 21d | — | — | — | — | 1 |
No neoadjuvant therapy Partial | — | — | — | — | 18.0 mo | — | — | 2 |
5 of 5 regimens shown